Tuesday, November 17, 2026

Kyobo Life Insurance Secures Six Exclusive-Use Rights in One Year, the Most in the Life Insurance Industry

Input
2026-11-17 10:47:21
Updated
2026-11-17 10:47:21
Kyobo Life Insurance’s Gwanghwamun headquarters. Newsis

[Financial News] Kyobo Life Insurance has secured the most exclusive-use rights in the life insurance industry over the past year. This follows continued development of products that expand the coverage of existing insurance, from underwriting to genetic testing, emergency treatment and hospitalization for stroke.
According to the Korea Life Insurance Association on the 17th, Kyobo Life Insurance obtained a total of six exclusive-use rights from November 2025 through October 2026. The rights grant insurance products or riders recognized for their originality and usefulness exclusive sales rights for a set period; during that period, other insurers cannot sell similar products.
In October, the stroke intensive care unit inpatient treatment rider under Kyobo My Plan Health Insurance II (Non-Participating) received a six-month exclusive-use right. It provides separate coverage for inpatient treatment in a stroke intensive care unit, in addition to general wards and intensive care units.
In July, the multiple-review underwriting rider under Kyobo K-Customized Health Insurance secured a six-month exclusive-use right. It distinguishes between standard and simplified underwriting for each type of coverage, helping reduce unnecessary premium surcharges.
In February this year, two riders related to cardiopulmonary resuscitation and defibrillation under Kyobo My Plan Health Insurance each received a six-month exclusive-use right. They also cover emergency treatment for acute cardiac arrest caused by accidents as well as illness.
Coverage related to women's health was also expanded. The specific uterine disease coverage rider under Kyobo Double-Up Women's Health Insurance received a six-month exclusive-use right by covering the cost of covered ultrasound examinations. In November last year, the company secured a three-month exclusive-use right for a rider covering the costs of genetic testing and next-generation sequencing (NGS) tests needed to diagnose hereditary cancers in women.
The insurance industry is watching the trend toward expanding insurance coverage beyond disease diagnosis and hospitalization to include actual testing and treatment, as medical technologies and treatment methods become more diverse.
A Kyobo Life Insurance representative said, “As the medical environment and treatment methods change rapidly, the coverage customers need is also changing,” adding, “We will continue to introduce products that reflect the difficulties customers face during actual treatment.”

[email protected] Hong Yeji Reporter